Emergent BioSolutions Inc. (LON:0IGA)
5.67
-0.30 (-5.03%)
At close: Aug 1, 2025
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$830,233
Profits / Employee
-$113,175
Market Cap
230.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 900 | -700 | -43.75% |
Dec 31, 2023 | 1,600 | -900 | -36.00% |
Dec 31, 2022 | 2,500 | 84 | 3.48% |
Dec 31, 2021 | 2,416 | 216 | 9.82% |
Dec 31, 2020 | 2,200 | 366 | 19.96% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
Emergent BioSolutions News
- 5 days ago - Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - GlobeNewsWire
- 5 days ago - New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox - GlobeNewsWire
- 18 days ago - Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 24 days ago - Emergent BioSolutions (EBS) Expands Smallpox Vaccine Contract with US Government - GuruFocus
- 24 days ago - Emergent BioSolutions signs contract modification award for CNJ-016 - Seeking Alpha
- 24 days ago - Emergent Biosolutions secures $51.9M contract modification award for smallpox preparedness - Seeking Alpha
- 24 days ago - Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - GlobeNewsWire